Cargando…
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive, incurable disease, characterized by a deregulated cell cycle. Chk1 and Wee1 are main regulators of cell cycle progression and recent data on solid tumors suggest that simultaneous inhibition of these proteins has a strong synergistic cytotoxic effect. The...
Autores principales: | Chilà, Rosaria, Basana, Alessandra, Lupi, Monica, Guffanti, Federica, Gaudio, Eugenio, Rinaldi, Andrea, Cascione, Luciano, Restelli, Valentina, Tarantelli, Chiara, Bertoni, Francesco, Damia, Giovanna, Carrassa, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413661/ https://www.ncbi.nlm.nih.gov/pubmed/25428911 |
Ejemplares similares
-
Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
por: Restelli, Valentina, et al.
Publicado: (2015) -
Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
por: Affatato, Roberta, et al.
Publicado: (2020) -
Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022) -
Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022) -
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
por: Tarantelli, Chiara, et al.
Publicado: (2018)